Good Morning AllI was disgnosed 6 years ago with oligometastic prostate cancer Gleeson 8, PSA 22. Since January 2018 I have been on ADT, had docetaxel chemo in April 2018, radiotherapy to the prostate, seminal vessel and pelvis in November 2018 when PSA dropped to <0.1. PSMA PET CT scan in March 2019 showed metastasis on spine and hip joint which were treated with SBRT. In 2022 PSA started rising to 3. New PSMA scan in April 2023 showed 3 new metastasis near the prostate and PSA up to 5.4. Started Xtandi 160 mg/di in April which pushed PSA back down to <0.1 but ALT liver enzyme up to 560 (ULN 59). This forced stopping Xtandi for 4 weeks until ALT was down to 69. Restarted Xtandi 4 weeks ago on 80 mg/di. Today ALT 38 and PSA still <01. My oncology team now wants to bring the dose back up to the standard of 160 mg/di.
My question: Should I stay on 80 mg/di until PSA rises again? Would this possibly extend the overall efficacy life span of enzalutamide?
I am fit, very active and pain and side effect free apart from peripheral neuropathy in my feet caused by the chemo.
I look forward to your views, experience with Xtandi and advice. Thank you.
KGU